Central administration of the TLR4 inhibitor TAK242 enhanced leptin-induced suppression of food intake in rats with diet-induced obesity, but did not exert additive effects in RYGB-treated animals, indicating that RYGB may exert its benefits through this mechanism. The gene discussed is LEP; the disease is Obesity.